Year-end Sale % OFF 
Abstract
The management of radioiodine refractory -RAIR) thyroid cancers (TC), metastatic medullary thyroid cancer (MTC), and anaplastic thyroid cancer (ATC) has recently changed with the arrival of new treatments that target specific molecular abnormalities. Differences in the ability to offer molecular somatic screening and targeted treatments can lead to disparities in cancer care among different European countries.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
